Clinical trials: Behavior Therapy
Agitation Associated With, Alzheimer's Disease
A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation
To compare the efficacy of 2 fixed doses of brexpiprazole with placebo in participants with agitation associated with dementia of the Alzheimer's type.
- Conditions
- Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder
- Trial name
- NCT01862640
- Testing
- Brexpiprazole, OPC-34712
- Where
- 85 sites in United States, Croatia and 5 more
- Volunteers
- 433 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Haemophilia A, Haemophilia B
A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia
The Hemophilia Growth and Development Study (HGDS) nearly 25 years ago showed haemophilia and HIV impacted brain development, thinking, and behaviour in children and adolescents.
- Trial name
- eTHINK (NCT03660774)
- Testing
- No treatment given
- Where
- 22 sites in United States
- Volunteers
- 563 people
- Sponsor
- Novo Nordisk A/S
Performance and Tolerance of Colonoscopy
Carolina-ColoWrap® in Colonoscopy Performance and Outcomes Study
Colonoscopy is the gold-standard for colorectal cancer screening in the US. However, complete colonoscopy can be a challenging technical procedure, even for expert gastroenterologists due to variations in patient anatomy…
- Trial name
- C3PO (NCT02025504)
- Testing
- ColoWrap
- Where
- 3 sites in United States
- Volunteers
- 350 people
- Sponsor
- ColoWrap, LLC
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukaemias (AML)
Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies
The primary goal of this study is to evaluate an alternative myeloablative, but reduced toxicity conditioning regimen in children, to describe the safety and efficacy of intravenous (i.v.) Treosulfan administered as part of a…
- Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukaemias (AML), Myelodysplastic Syndromes (MDS), Juvenile Myelomonocytic Leukaemias (JMML)
- Trial name
- NCT02333058
- Testing
- Treosulfan
- Where
- 24 sites in Austria, Czechia and 4 more
- Volunteers
- 70 people
- Sponsor
- medac GmbH
Pulmonary Hypertension
Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
This pilot, non-interventional, company-sponsored, multi-center study documents observational data on patients under routine treatment of Pulmonary Arterial Hypertension (PAH) with inhaled iloprost (using I-Neb device for the…
- Trial name
- COMPHI (NCT01894035)
- Testing
- Iloprost (Ventavis, BAYQ 6256)
- Where
- Portugal
- Volunteers
- 13 people
- Sponsor
- Bayer
Patient Activation
Induced Physiological Ketosis in Asthenia and\or Decreased Tolerance to Physical and\or Mental Exertion
The purpose of this study is evaluating of efficacy of innovative dietary strategy -stimulation of physiological ketosis with Liquid Technology Formula PanTrek, in patients with asthenia and or decreased tolerance to physical…
- Trial name
- NCT05689697
- Testing
- PanTrek
- Where
- Russia
- Volunteers
- 88 people
- Sponsor
- Ketonic Pharm LLC
Hemophilia A, Prophylaxis of Bleeding
An Observational Study Called JOIHA to Learn More About How Well the Treatment With Jivi Works to Prevent Problems With Joints in Adults With Hemophilia A.
This is an observational study in which data from people with hemophilia A who decide on their own or by recommendation of their doctors to take Jivi are collected and studied.
- Trial name
- JOIHA (NCT05643560)
- Testing
- Damoctocog alfa pegol (Jivi, BAY94-9027)
- Where
- Italy
- Volunteers
- 33 people
- Sponsor
- Bayer
Major Depressive Disorder
Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to determine the long-term efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.
- Trial name
- NCT00707980
- Testing
- Vortioxetine
- Where
- 92 sites in United States, Australia and 15 more
- Volunteers
- 836 people
- Sponsor
- Takeda
Job Stress, Distress, Emotional
Depression Return to Work Intervention
This study is a randomized controlled trial to test the effectiveness of a mobile app-based program aimed to help individuals with unemployment-related emotional distress return to work.
- Trial name
- DRIVEN (NCT06026280)
- Testing
- DRIVEN Application, Career Resources
- Where
- United States
- Volunteers
- 141 people, healthy volunteers welcome
- Sponsor
- Inspiration at Work
Depressive Disorder, Major
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms.
- Trial name
- RENEW-MDD-1 (NCT07412756)
- Testing
- Brenipatide
- Where
- 181 sites in United States, Australia and 13 more
- Volunteers
- 1,000 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
- Trial name
- NCT06786624
- Testing
- NBI-1065845
- Where
- 18 sites in United States
- Volunteers
- 200 people
- Sponsor
- Neurocrine Biosciences
Smoking Cessation
Cumulative Skin Irritation Potential of a New 15 mg Nicotine Patch
An investigation on the cumulative skin irritation potential of a newly developed 15 mg nicotine patch. Evaluation of skin irritation of a newly developed 15 mg nicotine transdermal patch.
- Trial name
- NCT00965913
- Testing
- Nicotine Patch, Nicotine Patch Comparator
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- McNeil AB
Depressive Disorder, Treatment-Resistant
Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression
This study evaluated the efficacy and safety of the compound MIJ821 compared to placebo in patients aged from 18 to 65 years diagnosed with treatment-resistant depression. The study was conducted in the US and in Europe (Spain).
- Trial name
- NCT03756129
- Testing
- MIJ821, Ketamine
- Where
- 12 sites in United States, Spain
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Pain
Identification of Predictive Factors for observAnce of Transcutaneous Electrical NeuroStimulation (TENS) in Chronic Pain
This is a retrospective and transverse multicenter study to identify predictive factors for adherence to TENS by chronic pain patients followed in structures specialized in Chronic Pain management (SPC).
- Trial name
- IPATENS (NCT04253639)
- Testing
- Questionnaires
- Volunteers
- 500 people
- Sponsor
- Sublimed
Major Depressive Disorder
Software Treatments for Actively Reducing Severity of Cognitive Deficits in MDD (STARS-MDD)
The purpose of this study is to evaluate the effects of videogame-like digital therapies as adjunct therapy to antidepressant medications on cognitive deficits associated with major depressive disorder.
- Trial name
- NCT03310281
- Testing
- HOLD: Videogame
- Where
- 4 sites in United States
- Volunteers
- 84 people
- Sponsor
- Akili Interactive Labs, Inc.
Attention-deficit Hyperactivity Disorder
A Study to Examine the Progression of Attention-Deficit Hyperactivity Disorder (ADHD) Drug Treatment and to Analyze Associated Factors
The purpose of this observational study is to explore the efficacy of methylphenidate hydrochloride in children and adolescents diagnosed with attention-deficit hyperactivity disorder (ADHD) by Kiddie-scheduled for affective…
- Trial name
- NCT01624649
- Testing
- Methylphenidate hydrochloride, Atomoxetine
- Where
- 9 sites in South Korea
- Volunteers
- 289 people
- Sponsor
- Janssen Korea, Ltd., Korea
Attention Deficit Hyperactivity Disorder, Substance Use Disorders
CBT for Patients With Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorders
The purpose of this study is to determine if cognitive behavioral therapy is effective in treating ADHD symptoms in patients with substance use disorders and comorbid ADHD.
- Trial name
- NCT01431235
- Testing
- cognitive behavioral therapy for treating ADHD symptoms
- Where
- Netherlands
- Volunteers
- 184 people
- Sponsor
- Arkin
Restless Legs Syndrome, Moderate to Severe Idiopathic Restless Legs Syndrome (RLS)
The Effects Of Ropinirole On Mood Or Mild Depression In Patients With Moderate To Severe Restless Legs Syndrome
Ropinirole has shown to improve mood in depressed patients as well as to improve the symptoms of Restless Legs Syndrome. Up to 40% of RLS patients suffer from mild depression, therefore it would be important for decisions no…
- Trial name
- NCT00357097
- Testing
- Ropinirole
- Where
- 50 sites in Germany
- Volunteers
- 240 people
- Sponsor
- GlaxoSmithKline
Fertility, Male Fertility
Sperm, Exposure and Endocrine Disruptors
The proposed research aims to 1) measure male participants' urinary levels of EDCs and sperm quality before and after report-back and EDC reduction intervention and assess changes, 2) assess the extent to which MM's program…
- Conditions
- Fertility, Male Fertility, Sperm Count, Low, Sperm Quality
- Trial name
- SEED (NCT07703046)
- Testing
- EDC Education Intervention
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Million Marker Wellness, Inc.
Major Depressive Disorder
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Major Depressive Disorder
This study is to evaluate that (SEROQUEL®) quetiapine sustained-release is efficacious and safe in the treatment of patients with MDD.
- Trial name
- MOONSTONE (NCT00320268)
- Testing
- Quetiapine fumarate
- Where
- 37 sites in United States
- Volunteers
- 600 people
- Sponsor
- AstraZeneca